Comment from Mykola Vizir

Summary: The commenter, a pharmaceutical quality-control and analytical-development professional, supports the adoption of the ICH M4Q(R2) guideline as a step toward digitalization and clearer lifecycle management. They propose specific modifications to the dossier structure to explicitly define "critical sample-preparation parameters" and to provide a designated location for documenting AI-assisted or algorithmic decision-support tools.